Kyorin Pharmaceutical Co., Ltd. (4569.T) Stock

4569.T logo

Kyorin Pharmaceutical Co., Ltd.

4569.TJapan
Healthcare

Company profile

Kyorin Pharmaceutical reported revenue of 130.09 billion JPY for fiscal year 2025, up 8.8% from fiscal year 2024, and net income of 9.09 billion JPY. That is a net profit margin of 7.0% for fiscal year 2025. Japan was its largest region in fiscal year 2025, with 90% of revenue. Our analysis of its filings shows revenue growing from 113.27 billion JPY in fiscal year 2023 to 130.09 billion JPY in fiscal year 2025, 7.2% a year on average. Kyorin Pharmaceutical reports about 1,982 full-time employees.

What stands out

  • Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended March 31, 2025.

About Kyorin Pharmaceutical Co., Ltd.

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells generic drugs in Japan and internationally. The company is also involved in drug discovery and licensing activities. It also offers infectious disease-related products; over-the-counter drug; and generic drugs. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.

Largest shareholders

  • Ogihara Family13.34 %13.34%
  • Kopernik Global Investors LLC8.75%
  • Luchesu KK6.19%
  • Shochans KK5.91%
  • Kyorin Group Employee Ownership Plan3.49%

Share of the company, as of September 25, 2026

Leadership

  • Yutaka Ogihara — President, CEO & Chairman, 58
  • Kenichi Nakamura — Managing Exec. Officer, CMO & President of KYORIN Pharma Grp Fac Co., Ltd.
  • Yasuji Kurose — CFO, CSO, Managing Executive Officer, Director of Corporate Planning & Executive Director, 55
  • Junichi Ishiyama — Managing Executive Officer, CSO & Head of Drug Discovery Div.
  • Noriaki Tamura — Managing Executive Officer, CCO, Head of Pharmaceutical Sales Division & Director, 59

How much revenue does Kyorin Pharmaceutical make?

Kyorin Pharmaceutical reported 130.09 billion JPY in revenue for fiscal year 2025, up 8.8% from 119.53 billion JPY in fiscal year 2024.

Where does Kyorin Pharmaceutical make most of its revenue?

Japan: 90% of revenue by region in fiscal year 2025, followed by Overseas (10%).

What companies are similar to Kyorin Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Katakura Industries Co.,Ltd. (3001.T), Mochida Pharmaceutical Co., Ltd. (4534.T), Zeria Pharmaceutical Co., Ltd. (4559.T), Aska Pharmaceutical Holdings Co.,Ltd. (4886.T).

How has Kyorin Pharmaceutical's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 102.90 billion JPY; FY2022, 105.53 billion JPY; FY2023, 113.27 billion JPY; FY2024, 119.53 billion JPY; FY2025, 130.09 billion JPY.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees1,982
FoundedOct 31, 1958
IPO DateMar 10, 2006
IPO StatusPublic
HeadquartersTokyo, Japan
ExchangeTokyo
TimezoneAsia/Tokyo (JST)

Contact & Links

Address
A, Tokyo, 100-0004
Phone
81 3 6374 9700
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Kyorin Pharmaceutical Co., Ltd. (4569.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4569.T

LinkedInLinkedInXXYouTubeYouTube